do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline GLP-1-RA and

GLP 1 receptor agonists should not be combined with DPP 4 inhibitors, as there is no added glucose lowering benefit beyond that of the GLP 1 RA alone. Both drug classes work through overlapping mechanisms involving Drug Focus: Saxenda (Liraglutide) As pharmacological management of obesity becomes more prevalent, understanding the mechanism of GLP 1 agonists is key. Key Clinical Pearls: MOA: Mimics native GLP 1 to regulate appetite You've probably heard about GLP 1 medications. But do you know how Medicare coverage is changing? Starting July 1, 2026, some Medicare beneficiaries may qualify to receive certain GLP 1 medications for about $50 Costly GLP 1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans KFF Use of DPP4 Inhibitors and GLP 1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study Clinical Gastroenterology and Hepatology